18F-sodium fluoride positron emission tomography and near-infrared spectroscopy intravascular ultrasound for evaluation of coronary artery plaques in stenosis with deferred revascularization based on fractional flow reserve - 18F-NaF PET and NIRS-IVUS for evaluation of coronary plaques

Start Date02 Apr 2023

Sponsor / Collaborator-

NCT04981509 / RecruitingPhase 2IIT

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.

Start Date10 Jun 2022

Sponsor / Collaborator

National Cancer Institute

NCT05527483 / CompletedNot ApplicableIIT

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) for detection of bone metastasis in patients with prostate cancer.
For imaging the investigators will use a FDA approved imaging technology, digital Positron Emission Tomography (PET/CT). The investigators would like to know if digital PET/CT using [Ga-68]PSMA provides accurate information about the extent of bone metastases.
Therefore, the investigators will compare[Ga-68]PSMA PET/CT with Flourine-18 [F-18] Sodium Fluoride (NaF), which is a high resolution bone scan. [F-18]NaF is FDA approved and the reference standard for evaluating the presence of bone metastases.[Ga-68]PSMA is an investigational (experimental) drug that works by binding to Prostate Specific Membrane Antigen, which is overexpressed in prostate cancer. [Ga-68]PSMA is experimental because it is not approved by the Food and Drug Administration (FDA) at University Hospitals. However, FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application.

Start Date21 Apr 2022

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

100 Clinical Results associated with SODIUM FLUORIDE F-18

100 Translational Medicine associated with SODIUM FLUORIDE F-18

100 Patents (Medical) associated with SODIUM FLUORIDE F-18

Literatures (Medical) associated with SODIUM FLUORIDE F-18

01 Dec 2023·Clinical Nuclear Medicine

Simultaneous Uptake of 18F-NaF and 18F-FDG by Bladder and Prostate Calculi

Article

Author: Alavi, Abass ; Høilund-Carlsen, Poul F ; Park, Mia Mijung ; Werner, Thomas J ; Park, Peter Sang Uk

AbstractCalcification and formation of calculi in the genitourinary system such as the bladder, kidney, and prostate are common processes of aging. Despite being in different parts of the body, these calculi can share risk factors; for instance, bladder and prostate calculi are seen in older men with benign prostatic hyperplasia. There have been increasing reports of detection of calculi using PET tracers such as 18F-NaF and 18F-FDG, suggesting their role for detection of extraosseous calcification. In this report, we present simultaneous detection of bladder and prostate calculi with both 18F-NaF and 18F-FDG avidity in a 74-year-old man with multiple myeloma.

22 Sep 2023·bioRxiv : the preprint server for biology

Flexible 3-D Electrochemical Impedance Spectroscopy Sensors Incorporating Phase Delay for Comprehensive Characterization of Atherosclerosis.

Author: Suwannaphoom, Krit ; Duarte, Sandra ; Packard, René R Sevag ; Tamboline, Mikayla ; Xu, Shili ; Neverova, Natalia ; Lluri, Gentian ; Chen, Michael ; Fishbein, Michael C ; Luo, Yuan

BackgroundDistinguishing quiescent from rupture-prone atherosclerotic lesions has significant translational and clinical implications. Electrochemical impedance spectroscopy (EIS) characterizes biological tissues by assessing impedance and phase delay responses to alternating current at multiple frequencies.We evaluated invasive 6-point stretchable EIS sensors over a spectrum of experimental atherosclerosis and compared results with intravascular ultrasound (IVUS), molecular positron emission tomography (PET) imaging, and histology.MethodsMale New Zealand White rabbits (n=16) were placed on a high-fat diet for 4 or 8 weeks, with or without endothelial denudation via balloon injury of the infrarenal abdominal aorta. Rabbits underwent in vivo micro-PET imaging of the abdominal aorta with ⁶⁸ Ga-DOTATATE, ¹⁸ F-NaF, and ¹⁸ F-FDG, followed by invasive interrogation via IVUS and EIS. Background signal corrected values of impedance and phase delay were determined. Abdominal aortic samples were collected for histological analyses. Analyses were performed blindly.ResultsPhase delay correlated with anatomic markers of plaque burden, namely intima/media ratio (r=0.883 at 1 kHz, P =0.004) and %stenosis (r=0.901 at 0.25 kHz, P =0.002), similar to IVUS. Moreover, impedance was associated with markers of plaque activity including macrophage infiltration (r=0.813 at 10 kHz, P =0.008) and macrophage/smooth muscle cell (SMC) ratio (r=0.813 at 25 kHz, P =0.026). ⁶⁸ Ga-DOTATATE correlated with intimal macrophage infiltration (r=0.861, P =0.003) and macrophage/SMC ratio (r=0.831, P =0.021), ¹⁸ F-NaF with SMC infiltration (r=-0.842, P =0.018), and ¹⁸ F-FDG correlated with macrophage/SMC ratio (r=0.787, P =0.036).ConclusionsEIS with phase delay integrates key atherosclerosis features that otherwise require multiple complementary invasive and non-invasive imaging approaches to capture. These findings indicate the potential of invasive EIS as a comprehensive modality for evaluation of human coronary artery disease.GRAPHICAL ABSTRACTHIGHLIGHTSElectrochemical impedance spectroscopy (EIS) characterizes both anatomic features - via phase delay; and inflammatory activity - via impedance profiles, of underlying atherosclerosis.EIS can serve as an integrated, comprehensive metric for atherosclerosis evaluation by capturing morphological and compositional plaque characteristics that otherwise require multiple imaging modalities to obtain.Translation of these findings from animal models to human coronary artery disease may provide an additional strategy to help guide clinical management.

01 Sep 2023·Clinical nuclear medicine

Comparison of Oral and IV 18 F-NaF PET/CT Administration in the Assessment of Bone Metastases in Patients With Breast or Prostate Cancers.

Article

Author: Sado, Heitor Naoki ; Buchpiguel, Carlos Alberto ; Zacchi, Samara Riguete ; Rocha, Nelisa Helena ; Sapienza, Marcelo Tatit ; Duarte, Paulo Schiavom

PURPOSEThe aim of this study was to compare oral and IV administrations of 18 F-NaF PET/CT for detection of suspicious bone metastatic lesions of breast and prostate cancers.PATIENTS AND METHODSThirty-six patients with breast (n = 23) or prostate (n = 13) cancers and high risk for bone metastases were prospectively evaluated. All patients underwent 2 PET/CT studies after IV and oral 18 F-NaF administration within a 2 to 23 days interval between them. The maximum SUVs from the same suspicious lesions (≤5 index lesions per patient) in both studies were measured. The target-to-background ratio (TBR), defined as the relation between the lesion maximum SUV and the whole skeletal mean SUV, was calculated for each lesion. The TBRs in the same lesion calculated using the 2 administration routes were compared. The agreements between 2 physicians in the definition of the number of lesions in both studies were also assessed using weighted κ.RESULTSOne hundred thirty-four pairs of lesions were analyzed. There was no significant statistical difference between the median TBRs ( P = 0.212) for IV (10.33) and oral (10.85). Excellent intraobserver agreement was observed between IV and oral routes: weighted κ of 1.0 (95% confidence interval, 0.92-1.0) and 0.92 (95% confidence interval, 0.81-0.99) for physicians 1 and 2, respectively. The interobserver coefficients were 0.82 and 0.87 for "oral versus oral" and "IV versus IV," respectively.CONCLUSIONS18 F-NaF PET/CT studies using oral and IV routes present comparable performance; thus, it is possible to use oral route in patients with difficult venous access.

News (Medical) associated with SODIUM FLUORIDE F-18

03 Jan 2024

·www.pmlive.com

ICR study predicts response to radium-233 treatment in prostate cancer bone metastases

Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have discovered a way to predict which patients are likely to respond to radium-233 treatment in prostate cancer bone metastases. Researchers analysed 133 lesions in 36 patients living with castration-resistant prostate cancer that had spread only to the bones. Prostate cancer occurs in the prostate gland, which sits just below the bladder in males. A previous autopsy study revealed that 90.1% of men who died with metastases of prostate cancer were diagnosed with bone metastases. Using whole-body MRIs with diffusion-weighted imaging, researchers monitored changes in the apparent diffusion coefficient (ADC) to indicate the movement of water in tissue at the beginning of the study and every eight weeks throughout. Within tissues, the lower the ADC, the higher the cellular density of the tumour – a major hallmark of more aggressive cancer types. After researchers carried out 18F-sodium fluoride PET scans with 18F-NaF and 18F-choline, they found that the uptake of 18F-NaF by metastases was significantly higher in those that produced an increase in ADC of 30% or more. Using this technique, researchers were able to determine where radium-233, an internal form of radiotherapy, would be most effective, as 18F-NaF has a similar structure to calcium, which is key for bone development and metabolism. Using a PET scan, researchers could reveal the areas with the highest uptake of 18F-NaF to show where radium-233 treatment would most likely be effective. In a further ICR-led study published in JNCI Cancer Spectrum , researchers were able to assess responses to radium-233 using diffusion-weighted MRI to study the movement of water molecules in tissues and found that some patients benefitted from radium-233 treatment much more than others. The findings from both studies could further improve the treatment of advanced prostate cancer that has spread to the bones and could help clinicians determine which patients will more likely respond to radium-233 treatment. Consultant radiologist, functional imaging, the Royal Marsden and professor of functional cancer imaging at ICR, Dow-Mu Koh, said: “Our findings demonstrate how sensitive imaging is and how it can be used for targeted treatments.”

Clinical ResultRadiation Therapy

16 Jul 2021

·www.globenewswire.com

Preference for Advanced Technology is Accelerating Demand

PUNE, India, July 16, 2021 (GLOBE NEWSWIRE) -- The Global Nuclear Imaging Equipment Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis. Nuclear imaging equipment market size was estimated to be US$ 3.65 billion in 2020 and is expected to reach US$ 5.9 billion by 2031 at a CAGR of 4.5%. Nuclear imaging technique alludes to a non-intrusive, easy indicative assessment that permits specialists to analyze the ailment of patients. To give pictures of how tissues and organs work, nuclear imaging uses radioisotopes that are embedded into the blood circulation system, gulped, or breathed in. For imaging, nuclear imaging hardware utilizes radioactive materials/tracers. These photos help the recognizable proof and forecast of the illness by specialists and clinicians. Because of atherosclerosis, PET imaging may identify dynamic vascular macrocalcification along with the radioactive component 18F-sodium fluoride. Growth driving factors of Global Nuclear Imaging Equipment Market Aspects driving business sector income development are fixated around customized drugs and innovative technology in radiotracers. Besides, development is postulated to improve by extension of drug enterprises and rising predominance of ongoing illnesses like malignant growth, namely, tumor and cancer. As articulated by a World Health Organization (WHO) study, continual sicknesses for a long period of time represented around 3/4 of all deaths internationally in 2020. View the Entire report with Table of Contents: Individuals perform normal registration to test for sickness related signs, bringing about a quick demand for instrumentation for nuclear imaging. In the coming years, oncology screening techniques upheld by clinical imaging gear are relied upon to prompt considerable development. The cardiology market segment is postulated to see critical development during the projected period. This is owing to the expanding number of individuals experiencing cardiovascular disorders, expanding consciousness of heart issues, expanding unhealthy lifestyle choices, the intensifying evolution of infection is relied upon to develop fundamentally throughout the next few years. Nuclear imaging innovation head ways have been displayed to give productive patient care to tumor diagnosis along with accuracy of imaging techniques for clinical preliminaries. For instance, at the World Molecular Imaging Congress, in September 2018, in Seattle, Bruker divulged a preclinical PET/CT Si78 scanner for entire body atomic imaging. Micro-Computed Tomography (CT) and Positron Emission Tomography (PET) advances, just as the imaging programming interface ParaVision 360, are consolidated in a solitary scanner. In any case, significant expense of nuclear imaging gear, expanding use and complexity of assembling and hardware methodology, and the absence of qualified experts to work such innovation are the main considerations that will restrict the market's development partially during the forecast period 2021-2031. Access Sample Pages of this Report: Restricted radio pharmaceutical endurance, high support expenses, and shortage of radionuclide Tc99m that is technetium 99 additionally present difficulties to showcase improvement. Tc99m is a radioisotope that is frequently utilized in nuclear medication scans to picture the patient's body. The leading market segments of Global Nuclear Imaging Equipment Market The Single Photon-Emission Computed Tomography (SPECT) imaging models represented the biggest income share in the worldwide market during 2020 because of its lesser cost when contrasted with crossover PET (Positron Emission Tomography) imaging models. The oncology segment is anticipated to enlist a critical CAGR during the forecast period of 2021-2031 because of rising event of tumors and cancers worldwide. The medical clinics segment represented the biggest income share among end client segments in the worldwide market in 2020 because of huge extent of approvals and usage of cutting edge nuclear imaging models. North America is relied upon to rule the worldwide the nuclear imaging gear market during 2019, while the Asia Pacific province is postulated to enlist the most elevated CAGR during the forecast period. The high development in this district can be credited to the expanding rate of persistent illnesses, rising attentiveness to the advantages of early and prompt sickness determination, along with improvement of medical services models in the area. Related report: Global Deep Brain Stimulation Devices Market: Global Scoliosis Management Market: Global Sickle Cell Disease Treatment Market: Besides, in the Asia-Pacific province, a huge CAGR rate over the standard time span will be exemplified. The development can be ascribed to the raised commonness of disease combined with vital approaches and demand in the medical care sector. The process of nuclear medication in Japan is profoundly best in class, with a critical spike in the quantity of half-and-half SPECT/CT tests in recent years. Besides, the developing clinical travel for medical purposes, are significant aspects influencing the development of the province. In 2018, Regal Philips belonging to the Netherlands and Local Health District (Australia) and Nepean Blue Mountains Local Health District (Australia) went into two 20-year arrangements for Managed Equipment Services, where Philips has consented to give, overhaul, convey, upgrade, supplant, and offer upkeep administrations for all significant clinical imaging arrangements in Australia and the Asia Pacific province. The key players of the Global Nuclear Imaging Equipment Market are: Siemens Healthineers, Koninklijke Philips N.V., GE Healthcare, Toshiba Medical Systems Corporation, Neusoft Medical Systems Co., Ltd., Mediso Medical Imaging Systems Co., Ltd., CMR Naviscan Corporation, Digirad Corporation, SurgiEye GmbH, and Positron Corporation, and others. Buy This Report: Global Nuclear Imaging Equipment Market Key Segments: Based on Type Based on Application Type Based on End user Type By Region insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com. Contact Us: Alex, insightSLICE Phone (USA): +1 707 736 6633 Email address: alex@insightslice.com Web:

Best in Class

100 Deals associated with SODIUM FLUORIDE F-18

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09IX06	DB09325

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	CN	JYAMS PET Research & Development Ltd.	19 Nov 2020
Diagnostic agents	Phase 3	US	GE Healthcare, Inc.	24 Feb 1972
Castration-Resistant Prostatic Cancer	Phase 2	US	National Cancer Institute	06 Jun 2017
Metastatic Prostate Carcinoma	Phase 2	US	National Cancer Institute	06 Jun 2017
Bone Cancer	Discovery	CN	HTA Co., Ltd.	29 Mar 2021
Bone metastases	Discovery	CN	HTA Co., Ltd.	29 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Plaque, Atherosclerotic	-	18F-sodium fluoride (Women)	qflvyuhdah(oucqpszyyc) = Following matching for plaque burden by coronary calcium scores and clinical comorbidities, there was no sex-related difference in CMA values (0.0 [0.0-1.12] versus 0.0 [0.0-1.23], p=0.21) and similar proportions of women and men had no 18F-NaF uptake (53.0% (n=80) and 48.3% (n=73); p=0.42), or CMA values >1.56 (21.8% (n=33) and 21.8% (n=33); p=1.00) ldavokjcmi (buuwesxcmj ) View more	-	01 Sep 2024
				18F-sodium fluoride (Men)
SNMMI2022	Not Applicable	-	-	18F-NaF PET/CT	oazdvinmhq(lpfpxhomzn) = pswverfoyo nlogrncpwz (gddhzbepfc ) View more	-	08 Aug 2022
				18F-NaF PET/CT (99mTc-MDP SPECT)	oazdvinmhq(lpfpxhomzn) = cyvuwnclvz nlogrncpwz (gddhzbepfc ) View more
SNMMI2021	Not Applicable	Angina Pectoris	-	18F-sodium fluoride (Healthy subjects)	giubymhvhn(vwnalwfgmr) = vupduenugc vgkgaojkrd (rluaijfkmp, 0.31) View more	-	18 May 2021
				18F-sodium fluoride (Angina pectoris patients)	giubymhvhn(vwnalwfgmr) = muwtljfblp vgkgaojkrd (rluaijfkmp, 0.35) View more
SNMMI2019	Not Applicable	Coronary Artery Disease	-	18F-Sodium fluoride (Patients with stable coronary artery disease and high-risk plaques (HRP) on coronary CTA)	cvwsicunlr(zxncdlfhwo) = ikxehwrtff rptdqiiagc (mdqnkbjnql ) View more	-	21 May 2019
SNMMI2019	Not Applicable	Calcification of coronary artery	-	18F-Sodium Fluoride (Healthy subjects)	mwgntdebok(altsrpndxi): β = 9.046 (95% CI, 4.06 - 14.031), P-Value = 0.001 View more	-	21 May 2019
				18F-Sodium Fluoride (Patients with chest pain syndrome)
ESC2018	Not Applicable	Aortic Valve Stenosis	58	18F-sodium fluoride	coyjvfmzgl(zzhjxcwxkv) = elcxhwepdt gegvhqxsft (yvzkytgxwu )	-	26 Aug 2018
				18F-sodium fluoride	coyjvfmzgl(zzhjxcwxkv) = xnqmapefru gegvhqxsft (yvzkytgxwu )
SNMMI2018	Not Applicable	Coronary angiography	-	18 F-NaF (ECG gated reconstruction)	bnjzmsxhik(iuybeybygl) = yphfpjhyld ijserogbag (znrovzpctj, 7.8 - 15.0) View more	-	23 May 2018
ESC2017	Not Applicable	Aortic Aneurysm, Abdominal	72	18F-Sodium fluoride	ihlbjgoxhw(wxjglrgtbr) = psxzjwxjdf fbcwvmxkjg (cjwbbpvvfi ) View more	-	28 Aug 2017
SNMMI2017	Not Applicable	Erectile Dysfunction NaF uptake	163	18 F-NaF (ED)	(kadrlfijry) = huwraicibz hnbjherlxc (lfivndbiwv, 4.5) View more	Positive	24 May 2017
				18 F-NaF (Future ED)	(kadrlfijry) = uhnxncmndo hnbjherlxc (lfivndbiwv, 5.8) View more
SNMMI2017	Not Applicable	Multiple Myeloma	-	18 F-NaF (MM lesions)	vhkuigfzmj(rgndrxttmn) = FD was significantly higher in degenerative than in malignant lesions cykgxwtnou (ayjiufqorf )	-	24 May 2017
				18 F-NaF (degenerative lesions)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis